Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine

Erika Pike; William W. Stoops; Craig R. Rush

doi:10.1016/j.pbb.2016.09.009

Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

There is not an approved pharmacotherapy for treating methamphetamine use disorder. This study sought to determine the effects of acute buspirone treatment on the subjective and cardiovascular effects of oral methamphetamine in order to provide an initial assessment of the utility, safety, and tolerability of buspirone for managing methamphetamine use disorder. We predicted that acute buspirone administration would reduce the subjective effects of methamphetamine. We also predicted that the combination of buspirone and methamphetamine would be safe and well tolerated. Ten subjects completed the protocol, which tested three methamphetamine doses (0, 15, and 30 mg) in combination with two buspirone doses (0 and 30 mg) across 6 experimental sessions. Subjective effects and physiological measures were collected at regular intervals prior to and after dose administration. Methamphetamine produced prototypical subjective and cardiovascular effects. Acute buspirone administration increased some of the abuse-related subjective effects of methamphetamine and also attenuated some cardiovascular effects. The combination of oral methamphetamine and buspirone was safe and well tolerated. Acute buspirone administration may increase the abuse liability of oral methamphetamine. Chronic buspirone dosing studies remain to be conducted, but given preclinical findings and the outcomes of this work, the utility of buspirone for treating methamphetamine use disorder appears limited.

Original language	English
Pages (from-to)	87-93
Number of pages	7
Journal	Pharmacology Biochemistry and Behavior
Volume	150-151
DOIs	https://doi.org/10.1016/j.pbb.2016.09.009
State	Published - Nov 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier Inc.

Funding

This research and the preparation of this manuscript were supported by grants from the National Institute on Drug Abuse R01DA025032 and R01DA025591 awarded to Dr. Craig Rush and the National Institute on Drug Abuse training grant T32DA035200 (CRR, EP). This funding source had no further role in study design; the collection, analysis, or interpretation of the data; writing of the report; or in the decision to submit the paper for publication. The authors declare no conflicts of interest.

Funders

Funder number

Author National Institute on Drug Abuse DA031791 Mark J Ferris National Institute on Drug Abuse DA006634 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA026117 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA028162 Elizabeth G Pitts National Institute of General Medical Sciences GM102773 Elizabeth G Pitts Peter McManus Charitable Trust Mark J Ferris National Institute on Drug Abuse

R01DA025032, R01DA025591, T32DA035200

Keywords

Acute
Buspirone
Cardiovascular effects
Methamphetamine
Subjective effects

ASJC Scopus subject areas

Biochemistry
Toxicology
Pharmacology
Clinical Biochemistry
Biological Psychiatry
Behavioral Neuroscience

Access to Document

10.1016/j.pbb.2016.09.009

Cite this

@article{808cd9d0bb964abf98035ba52613e579,

title = "Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine",

abstract = "There is not an approved pharmacotherapy for treating methamphetamine use disorder. This study sought to determine the effects of acute buspirone treatment on the subjective and cardiovascular effects of oral methamphetamine in order to provide an initial assessment of the utility, safety, and tolerability of buspirone for managing methamphetamine use disorder. We predicted that acute buspirone administration would reduce the subjective effects of methamphetamine. We also predicted that the combination of buspirone and methamphetamine would be safe and well tolerated. Ten subjects completed the protocol, which tested three methamphetamine doses (0, 15, and 30 mg) in combination with two buspirone doses (0 and 30 mg) across 6 experimental sessions. Subjective effects and physiological measures were collected at regular intervals prior to and after dose administration. Methamphetamine produced prototypical subjective and cardiovascular effects. Acute buspirone administration increased some of the abuse-related subjective effects of methamphetamine and also attenuated some cardiovascular effects. The combination of oral methamphetamine and buspirone was safe and well tolerated. Acute buspirone administration may increase the abuse liability of oral methamphetamine. Chronic buspirone dosing studies remain to be conducted, but given preclinical findings and the outcomes of this work, the utility of buspirone for treating methamphetamine use disorder appears limited.",

keywords = "Acute, Buspirone, Cardiovascular effects, Methamphetamine, Subjective effects",

author = "Erika Pike and Stoops, \{William W.\} and Rush, \{Craig R.\}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.pbb.2016.09.009",

language = "English",

volume = "150-151",

pages = "87--93",

}

TY - JOUR

T1 - Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine

AU - Pike, Erika

AU - Stoops, William W.

AU - Rush, Craig R.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - There is not an approved pharmacotherapy for treating methamphetamine use disorder. This study sought to determine the effects of acute buspirone treatment on the subjective and cardiovascular effects of oral methamphetamine in order to provide an initial assessment of the utility, safety, and tolerability of buspirone for managing methamphetamine use disorder. We predicted that acute buspirone administration would reduce the subjective effects of methamphetamine. We also predicted that the combination of buspirone and methamphetamine would be safe and well tolerated. Ten subjects completed the protocol, which tested three methamphetamine doses (0, 15, and 30 mg) in combination with two buspirone doses (0 and 30 mg) across 6 experimental sessions. Subjective effects and physiological measures were collected at regular intervals prior to and after dose administration. Methamphetamine produced prototypical subjective and cardiovascular effects. Acute buspirone administration increased some of the abuse-related subjective effects of methamphetamine and also attenuated some cardiovascular effects. The combination of oral methamphetamine and buspirone was safe and well tolerated. Acute buspirone administration may increase the abuse liability of oral methamphetamine. Chronic buspirone dosing studies remain to be conducted, but given preclinical findings and the outcomes of this work, the utility of buspirone for treating methamphetamine use disorder appears limited.

AB - There is not an approved pharmacotherapy for treating methamphetamine use disorder. This study sought to determine the effects of acute buspirone treatment on the subjective and cardiovascular effects of oral methamphetamine in order to provide an initial assessment of the utility, safety, and tolerability of buspirone for managing methamphetamine use disorder. We predicted that acute buspirone administration would reduce the subjective effects of methamphetamine. We also predicted that the combination of buspirone and methamphetamine would be safe and well tolerated. Ten subjects completed the protocol, which tested three methamphetamine doses (0, 15, and 30 mg) in combination with two buspirone doses (0 and 30 mg) across 6 experimental sessions. Subjective effects and physiological measures were collected at regular intervals prior to and after dose administration. Methamphetamine produced prototypical subjective and cardiovascular effects. Acute buspirone administration increased some of the abuse-related subjective effects of methamphetamine and also attenuated some cardiovascular effects. The combination of oral methamphetamine and buspirone was safe and well tolerated. Acute buspirone administration may increase the abuse liability of oral methamphetamine. Chronic buspirone dosing studies remain to be conducted, but given preclinical findings and the outcomes of this work, the utility of buspirone for treating methamphetamine use disorder appears limited.

KW - Acute

KW - Buspirone

KW - Cardiovascular effects

KW - Methamphetamine

KW - Subjective effects

UR - https://www.scopus.com/pages/publications/84990068251

UR - https://www.scopus.com/pages/publications/84990068251#tab=citedBy

U2 - 10.1016/j.pbb.2016.09.009

DO - 10.1016/j.pbb.2016.09.009

M3 - Article

C2 - 27697553

AN - SCOPUS:84990068251

SN - 0091-3057

VL - 150-151

SP - 87

EP - 93

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

ER -

Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this